Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neo-mDC
- Development stage
- Unknown
- Lead developer
- CellGENTherapies
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Neo-mDC is an autologous dendritic cell vaccine developed by CellGENTherapies in collaboration with Ghent University and UZ Gent. It is designed for the treatment of resected non-small cell lung cancer (NSCLC) to prevent disease recurrence. The vaccine is produced by isolating a patient's own dendritic cells and loading them with mRNA that encodes personalized, tumor-specific neoantigens identified through genomic sequencing of the patient's tumor. Once administered, these dendritic cells present the neoantigens to the immune system, specifically T cells, to stimulate a targeted immune response against residual cancer cells expressing those unique mutations. It is currently being evaluated in a Phase 1 clinical trial.
- Other names
- Neo-mDC vaccineneoantigen-targeted dendritic cell vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Neo-mDC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neo-mDC.